<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ILOPROST</span><br/>(i'lo-prost)<br/><b>Classifications:</b> <span class="classification">prostaglandin, antihypertensive</span>; <span class="classification">antiplatelet agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mcg/2 mL ampule</p>
<h1><a name="action">Actions</a></h1>
<p>Iloprost is a synthetic analog of prostaglandin. It dilates systemic and pulmonary arterial vascular beds. </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Dilation of the pulmonary arterial vessels reduces pulmonary hypertension.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of pulmonary arterial hypertension in patients with New York Heart Association (NYHA) class III or IV symptoms.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of severe Raynaud phenomenon associated with systemic sclerosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Lactation; children.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired hepatic function, elderly, pregnancy (category C), dialysis, concurrent use of vasodilators and/or antihypertensive
         drugs.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pulmonary Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Inhaled</span> 2.55 mcg 69 times daily, but no more than q2h during waking hours<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Inhalation</span><br/><ul>
<li>Transfer the contents of one ampule to the drug delivery system medication chamber immediately before use. Follow instructions
            provided by manufacturer for the delivery system. Do not allow contact with skin or eyes.
         </li>
<li>Do not administer if systolic BP is 
         </li><li>Do not administer any sooner than 2 h after the previous dose.</li>
<li>Discard any solution remaining in the medication chamber after the inhalation session.</li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache</span>, insomnia. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension</span>, <span class="speceff-common">vasodilation</span> (<span class="speceff-common">flushing</span>), palpitations, syncope, chest pain, <span class="speceff-life">tachycardia</span>, congestive heart failure. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea</span>, <span class="speceff-common">vomiting</span>. <span class="typehead">Hepatic:</span> Increased alkaline phosphatase, increased gamma-glutamyltransferase (GGT). <span class="typehead">Musculoskeletal:</span> Back pain, muscle cramps, <span class="speceff-common">trismus</span>. <span class="typehead"> Renal:</span> Kidney failure. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough</span>, dyspnea, hemoptysis, pneumonia, peripheral edema. <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Flu-like syndrom</span>e, tongue pain.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Enhanced hypotension when given with other <span class="classification">vasodilators</span> or <span class="classification">antihypertensive</span> agents; increased risk of bleeding when given with other <span class="classification">anticoagulants</span> or <span class="classification">antithrombotic</span> agents. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 60% protein bound. <span class="typehead">Metabolism:</span> Completely metabolized to inactive products. <span class="typehead">Elimination:</span> Urine (major) and feces. <span class="typehead">Half-Life:</span> 2030 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Supervise ambulation, especially with concurrent use of other drugs known to cause dizziness or syncope.</li>
<li>Monitor vital signs closely during initiation of drug therapy.</li>
<li>Monitor for and report S&amp;S of heart failure. </li>
<li>Withhold drug and notify physician if S&amp;S of pulmonary edema appear. </li>
<li>Lab tests: Monitor blood levels of anticoagulants when used concurrently.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow directions for taking the drug (see Administration). Iloprost inhalation should be used with the Prodose AAD system.
            Do not use it with other types of nebulizers.
         </li>
<li>Make position changes slowly, especially when arising from a chair or bed.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Report any of the following to a health care provider: dizziness or fainting, especially upon exertion, or increased difficulty
            breathing. 
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>